Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abuse-deterrent Immediate Release Oral Ketamine Capsules for Treatment Resistant Bipolar Depression
NCT07644767Phase 2Not yet recruiting
- Sponsor
- Neurocentrx Pharma
- Start
- Oct 2026
- Primary completion
- Jan 2028
01
Overview
A Phase 2 trial of ketotifen + acetylcysteine in bipolar disorder (BD), sponsored by Neurocentrx Pharma. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ketotifen + acetylcysteine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT07644767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07644767.